



INTERGENETICS RECEIVES \$300,000 MATCHING GRANT FOR COMMERCIAL DEVELOPMENT OF ITS BREAST CANCER RISK TEST

Oklahoma BioTech Company Awarded OCAST Grant to Complete Validation of OncoVue™ – Next Generation Breast Cancer Risk Test

For Immediate Release:

January 24, 2005

For More Information Contact:

Jane Braden 405 715-3232

OKLAHOMA CITY—The Oklahoma Center of the Advancement of Science & Technology (OCAST) has awarded a \$300,000 grant to Oklahoma-based InterGenetics Inc., a genetic cancer risk intervention company, to complete final work to commercialize the company's OncoVue™ Breast Cancer Risk Test through OCAST's Oklahoma Applied Research Support program. InterGenetics will match that funding to bring the total to \$600,000.

InterGenetics lead product OncoVue is the first breast cancer risk predictive test that can determine the lifetime and age-specific risk of developing breast cancer for all women. InterGenetics' scientists discovered that using algorithms that analyze combinations of multiple genes is a better way to determine breast cancer risk than previous assessment tests. Combinations of genes along with personal history measures help calculate a more complete genetic picture of breast cancer susceptibility by looking at interactions of genes that impact risk rather than the limited picture single genes can offer.

"The OCAST grant allows us to build upon the success of our research and development that clearly demonstrated the value of a multigenic approach to determining a woman's risk of developing breast cancer," said Dr. Craig Shimasaki, InterGenetics President and CEO. "We know OncoVue is a major breakthrough over standard breast cancer risk assessment tools in predicting the development of

breast cancer. By knowing who is at high risk, women can take preventative medications to reduce the occurrence of the disease or be screened with more comprehensive screening tools to catch breast cancer at its earliest stages where long term survival is the greatest.”

OncoVue is easy for women to use. Simply swish the mouthwash solution provided and deposit the fluid back into the tube provided. The DNA from the woman’s cheek cells is collected in the solution and analyzed in the InterGenetics laboratories along with the data from a medical questionnaire to assign a numeric value that represents her age-specific, life-time risk of developing breast cancer.

“We are pleased to support and promote research that will benefit women in Oklahoma and across the nation with such innovative science,” said Sheri Stickley, OCAST interim executive director. “OCAST awards vitally impact the medical community and the community as a whole, by investing in the future of companies like InterGenetics. “This test has already proven its revolutionary value in the early stages of research. This funding will allow InterGenetics to take their science to the next level and on to the commercial market.”

About InterGenetics

InterGenetics is an emerging life sciences firm dedicated to the pursuit of cancer genetics, cancer prevention, cancer diagnostics and cancer therapeutics. Scientists at InterGenetics have discovered a complex algorithm of multiple gene combinations related to breast and other cancers by testing more than a million combinations of genes. The company’s scientific advancements produced a breakthrough method to predict the risk of developing breast cancer and other cancers. The company expects to introduce its first commercial product, OncoVue™, a predictive risk assessment test for breast cancer, next year. For more information go to www.intergenetics.com.

About Oklahoma Center of the Advancement of Science & Technology

OCAST was created by the Oklahoma legislature in 1987 to build the infrastructure of expertise and equipment needed to conduct nationally competitive research and development in Oklahoma and stimulate Oklahoma firms applying and producing technology.

OCAST is committed to provide key financial, technical, and information resources to university and private sector innovators at critical points all along the technology pipeline from concept to commercialization.

Since its inception, OCAST has administered \$118 million in state-appropriated money and leverage \$12.67 for every dollar spent. That leverage represents more than \$1.6 billion invested in Oklahoma research over the past 16 years.

